Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 3/20 | 0.40 |
| ▸ | GCGR | P47871 | 9/20 | 0.38 |
| ▸ | GIPR | P48546 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | ABAT | P80404 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | GCG | P01275 | 2/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2652504 | 0.77 | KDM4E (0.43) | GCGRGIPRGCG | |
| SCHEMBL2651576 | 0.76 | EGLN1 (0.48) | GCGR | |
| SCHEMBL2652968 | 0.75 | PPARG (0.46) | GCGRGCGRORC | |
| SCHEMBL2651098 | 0.74 | KDM4E (0.46) | GCGRGIPRENPP2 | |
| SCHEMBL2651501 | 0.74 | GCGR (0.43) | GCGRGCGRORC | |
| SCHEMBL2653945 | 0.73 | GCGR (0.45) | GCGR | |
| SCHEMBL2653039 | 0.72 | MRGPRX1 (0.51) | GCGR | |
| SCHEMBL2655061 | 0.72 | PTGDR2 (0.46) | RORC | |
| SCHEMBL7113992 | 0.71 | SMN1; SMN2 (0.43) | GCGR | |
| SCHEMBL2651903 | 0.71 | HDAC1 (0.41) | GCGRGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212119-A1 | Novel glucagon receptor antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-11-13 | — | — | US | disclosed |
| WO-2003053938-A1 | BENZIMIDAZOLS AND INDOLS AS GLUCAGON RECEPTOR ANTAGONISTS/INVERSE AGONISTEN | NOVO NORDISK A/S (DK) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212119-A1 | Novel glucagon receptor antagonists/inverse agonists | GLP1R, GCGR, GIPR | IDH1 4449/4885GCGR 2/4885GIPR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.